Gilead Sciences Inc GILD
News
-
Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
-
FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
-
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
-
Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here.
-
Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
-
Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 — Data Talk
-
Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
-
Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.24B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 13.48
- Price/Sales
- 4.79
- Dividend Yield (Trailing)
- 2.86%
- Dividend Yield (Forward)
- 2.86%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 3.84%
Company Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 17,000
- Website
- https://www.gilead.com
Competitors
Valuation
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.48 | 45.36 | 11.46 |
Price/Book Value | 6.37 | 8.57 | 3.98 |
Price/Sales | 4.79 | 5.43 | 2.13 |
Price/Cash Flow | 11.12 | 16.30 | 9.11 |
Price/Earnings
GILD
MRK
GSK
Financial Strength
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
Quick Ratio
GILD
MRK
GSK
Profitability
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
Return on Assets
GILD
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|$W@f>Kl | LOCK|v^! | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|$^dGnRp | LOCK|Qx | $630B | |||
| AbbVie Inc
ABBV
| LOCK|?YZsjz | LOCK|kbL | $489B | |||
| Merck & Co Inc
MRK
| LOCK|^?QcM< | LOCK|%B! | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?DSSR!D% | LOCK|j? | $344B | |||
| Novartis AG ADR
NVS
| LOCK|F%&g$!%N | LOCK|<>r | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|wR<nD@?M | LOCK|@N | $246B | |||
| Amgen Inc
AMGN
| LOCK|<@Z!N>&C | LOCK|Kz | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|!#&^NcL | LOCK|w>f | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Rw^d>s% | LOCK|$@# | $169B |
United States